Christoph Scherfler1, Georg Göbel2, Christoph Müller2, Michael Nocker2, Gregor K Wenning2, Michael Schocke2, Werner Poewe2, Klaus Seppi2. 1. From the Departments of Neurology (C.S., C.M., M.N., G.K.W., W.P., K.S.), Medical Statistics, Informatics and Health Economics (G.G.), and Radiology (M.S.), Medical University of Innsbruck, Austria. christoph.scherfler@i-med.ac.at. 2. From the Departments of Neurology (C.S., C.M., M.N., G.K.W., W.P., K.S.), Medical Statistics, Informatics and Health Economics (G.G.), and Radiology (M.S.), Medical University of Innsbruck, Austria.
Abstract
OBJECTIVE: To determine whether automated and observer-independent volumetric MRI analysis is able to discriminate among patients with Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in early to moderately advanced stages of disease. METHODS: T1-weighted volumetric MRI from patients with clinically probable PD (n = 40), MSA (n = 40), and PSP (n = 30) and a mean disease duration of 2.8 ± 1.7 y were examined using automated volume measures of 22 subcortical regions. The clinical follow-up period was 2.5 ± 1.2 years. The data were split into a training (n = 72) and a test set (n = 38). The training set was used to build a C4.5 decision tree model in order to classify patients as MSA, PSP, or PD. The classification algorithm was examined by the test set using the final clinical diagnosis at last follow-up as diagnostic gold standard. RESULTS: The midbrain and putaminal volume as well as the cerebellar gray matter compartment were identified as the most significant brain regions to construct a prediction model. The diagnostic accuracy for PD vs MSA or PSP was 97.4%. In contrast, diagnostic accuracy based on validated clinical consensus criteria at the time of MRI acquisition was 62.9%. CONCLUSIONS: Volume segmentation of subcortical brain areas differentiates PD from MSA and PSP and improves diagnostic accuracy in patients presenting with early to moderately advanced stage parkinsonism. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that automated MRI analysis accurately discriminates among early-stage PD, MSA, and PSP.
OBJECTIVE: To determine whether automated and observer-independent volumetric MRI analysis is able to discriminate among patients with Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in early to moderately advanced stages of disease. METHODS: T1-weighted volumetric MRI from patients with clinically probable PD (n = 40), MSA (n = 40), and PSP (n = 30) and a mean disease duration of 2.8 ± 1.7 y were examined using automated volume measures of 22 subcortical regions. The clinical follow-up period was 2.5 ± 1.2 years. The data were split into a training (n = 72) and a test set (n = 38). The training set was used to build a C4.5 decision tree model in order to classify patients as MSA, PSP, or PD. The classification algorithm was examined by the test set using the final clinical diagnosis at last follow-up as diagnostic gold standard. RESULTS: The midbrain and putaminal volume as well as the cerebellar gray matter compartment were identified as the most significant brain regions to construct a prediction model. The diagnostic accuracy for PD vs MSA or PSP was 97.4%. In contrast, diagnostic accuracy based on validated clinical consensus criteria at the time of MRI acquisition was 62.9%. CONCLUSIONS: Volume segmentation of subcortical brain areas differentiates PD from MSA and PSP and improves diagnostic accuracy in patients presenting with early to moderately advanced stage parkinsonism. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that automated MRI analysis accurately discriminates among early-stage PD, MSA, and PSP.
Authors: Derek B Archer; Justin T Bricker; Winston T Chu; Roxana G Burciu; Johanna L Mccracken; Song Lai; Stephen A Coombes; Ruogu Fang; Angelos Barmpoutis; Daniel M Corcos; Ajay S Kurani; Trina Mitchell; Mieniecia L Black; Ellen Herschel; Tanya Simuni; Todd B Parrish; Cynthia Comella; Tao Xie; Klaus Seppi; Nicolaas I Bohnen; Martijn L T M Müller; Roger L Albin; Florian Krismer; Guangwei Du; Mechelle M Lewis; Xuemei Huang; Hong Li; Ofer Pasternak; Nikolaus R McFarland; Michael S Okun; David E Vaillancourt Journal: Lancet Digit Health Date: 2019-08-27
Authors: Iva Stankovic; Niall Quinn; Luca Vignatelli; Angelo Antonini; Daniela Berg; Elizabeth Coon; Pietro Cortelli; Alessandra Fanciulli; Joaquim J Ferreira; Roy Freeman; Glenda Halliday; Günter U Höglinger; Valeria Iodice; Horacio Kaufmann; Thomas Klockgether; Vladimir Kostic; Florian Krismer; Anthony Lang; Johannes Levin; Phillip Low; Christopher Mathias; Wassillios G Meissner; Lucy Norcliffe Kaufmann; Jose-Alberto Palma; Jalesh N Panicker; Maria Teresa Pellecchia; Ryuji Sakakibara; Jeremy Schmahmann; Sonja W Scholz; Wolfgang Singer; Maria Stamelou; Eduardo Tolosa; Shoji Tsuji; Klaus Seppi; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2019-04-29 Impact factor: 10.338
Authors: Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Codrin Lungu; F DuBois Bowman; Roy N Alcalay; Debra Babcock; Ted M Dawson; Richard B Dewey; Tatiana Foroud; Dwight German; Xuemei Huang; Vlad Petyuk; Judith A Potashkin; Rachel Saunders-Pullman; Margaret Sutherland; David R Walt; Andrew B West; Jing Zhang; Alice Chen-Plotkin; Clemens R Scherzer; David E Vaillancourt; Liana S Rosenthal Journal: Biomark Med Date: 2017-06-23 Impact factor: 2.851